Related Experiment Video
Updated: Jul 20, 2026
07:24
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
[New drugs for myeloma]
1Service d'Hématologie Clinique, CHU Hôtel-Dieu, Nantes. philippe.moreau@chu-nantes.fr
Presse Medicale (Paris, France : 1983)
|September 14, 2006
Summary
New myeloma treatments like thalidomide, bortezomib, and lenalidomide show promise for improving survival and managing relapsed multiple myeloma. These agents can be used alone or in combination, potentially replacing traditional chemotherapy.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Multiple myeloma relapse necessitates novel therapeutic strategies.
- Thalidomide, bortezomib, and lenalidomide represent key advancements in myeloma treatment.
- Understanding their mechanisms and toxicities is crucial for effective clinical application.
Purpose of the Study:
- To review the efficacy and safety of thalidomide, bortezomib, and lenalidomide in multiple myeloma.
- To explore their synergistic effects with dexamethasone and conventional chemotherapy.
- To assess their potential role in first-line treatment and management of relapsed disease.
Main Methods:
- Review of existing clinical studies and trial data.
- Analysis of drug mechanisms, toxicities, and synergistic interactions.
- Evaluation of treatment outcomes in first-line and relapsed settings.
Main Results:
- Thalidomide, bortezomib, and lenalidomide demonstrate efficacy in relapsed multiple myeloma.
- These agents show synergy with dexamethasone and can improve survival when combined with chemotherapy.
- Bortezomib is effective as induction treatment prior to autologous stem cell transplantation.
Conclusions:
- Thalidomide, bortezomib, and lenalidomide offer new therapeutic options for multiple myeloma.
- Sequential or combination use of these agents can transform myeloma into a chronic disease.
- These novel agents are poised to replace conventional chemotherapies in future treatment paradigms.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:10Drugs that Destabilize Microtubules
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...